X4 Pharma announces $65M PIPE and positive Phase 3 mavorixafor data in WHIM syndrome

X4 Pharmaceuticals, Inc

42.8M shares/pre-funded warrants priced at $1.52, raising $65M gross; expected close May 18, 2023.
Phase 3 4WHIM trial: mavorixafor reduced annualized infection rate by ~60% vs placebo (p<0.01).
Severe (Grade≥3) infections cut by 75%; mean infection duration reduced >70% (2 weeks vs 7 weeks on placebo).
NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023 after pre-NDA meeting with FDA.
Cash runway extended into Q4 2024, excluding potential priority review voucher proceeds.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.